



**HAL**  
open science

## Identification of Restricted Subsets of Mature microRNA Abnormally Expressed in Inactive Colonic Mucosa of Patients with Inflammatory Bowel Disease.

Magali Fasseu, Xavier Tréton, Cécile Guichard, Eric Pedruzzi, Dominique Cazals-Hatem, Christophe Richard, Thomas Aparicio, Fanny Daniel, Jean-Claude Soulé, Richard Moreau, et al.

### ► To cite this version:

Magali Fasseu, Xavier Tréton, Cécile Guichard, Eric Pedruzzi, Dominique Cazals-Hatem, et al.. Identification of Restricted Subsets of Mature microRNA Abnormally Expressed in Inactive Colonic Mucosa of Patients with Inflammatory Bowel Disease.. PLoS ONE, 2010, 5 (10), pp.e13160. 10.1371/journal.pone.0013160 . inserm-00528287

**HAL Id: inserm-00528287**

**<https://inserm.hal.science/inserm-00528287v1>**

Submitted on 21 Oct 2010

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# Identification of Restricted Subsets of Mature microRNA Abnormally Expressed in Inactive Colonic Mucosa of Patients with Inflammatory Bowel Disease

Magali Fasseu<sup>1,2,9</sup>, Xavier Tréton<sup>1,2,3,9</sup>, Cécile Guichard<sup>1,2</sup>, Eric Pedrucci<sup>1,2</sup>, Dominique Cazals-Hatem<sup>1,2,4</sup>, Christophe Richard<sup>1,2</sup>, Thomas Aparicio<sup>1,2,5</sup>, Fanny Daniel<sup>1,2</sup>, Jean-Claude Soulé<sup>1,2,5</sup>, Richard Moreau<sup>1,2</sup>, Yoram Bouhnik<sup>1,2,3</sup>, Marc Laburthe<sup>1,2</sup>, André Groyer<sup>1,2,\*†</sup>, Eric Ogier-Denis<sup>1,2†</sup>

**1** INSERM U773, Centre de Recherche Biomédicale Bichat Beaujon, Paris, France, **2** Université Paris 7 Denis Diderot, Paris, France, **3** Service de Gastroentérologie et d'Assistance Nutritive, Hôpital Beaujon, Clichy, France, **4** Service d'Anatomo-Pathologie, Hôpital Beaujon, Clichy, France, **5** Service de Gastroentérologie, Hôpital Xavier Bichat, Paris, France

## Abstract

**Background:** Ulcerative Colitis (UC) and Crohn's Disease (CD) are two chronic Inflammatory Bowel Diseases (IBD) affecting the intestinal mucosa. Current understanding of IBD pathogenesis points out the interplay of genetic events and environmental cues in the dysregulated immune response. We hypothesized that dysregulated microRNA (miRNA) expression may contribute to IBD pathogenesis. miRNAs are small, non-coding RNAs which prevent protein synthesis through translational suppression or mRNAs degradation, and regulate several physiological processes.

**Methodology/Findings:** Expression of mature miRNAs was studied by Q-PCR in inactive colonic mucosa of patients with UC (8), CD (8) and expressed relative to that observed in healthy controls (10). Only miRNAs with highly altered expression (>5 or <0.2 -fold relative to control) were considered when Q-PCR data were analyzed. Two subsets of 14 (UC) and 23 (CD) miRNAs with highly altered expression (5.2->100 -fold and 0.05–0.19 -fold for over- and under- expression, respectively; 0.001 < p ≤ 0.05) were identified in quiescent colonic mucosa, 8 being commonly dysregulated in non-inflamed UC and CD (mir-26a,-29a,-29b,-30c,-126\*, -127-3p,-196a,-324-3p). Several miRNA genes with dysregulated expression co-localize with acknowledged IBD-susceptibility loci while others, (eg. clustered on 14q32.31), map on chromosomal regions not previously recognized as IBD-susceptibility loci. In addition, *in silico* clustering analysis identified 5 miRNAs (mir-26a,-29b,-126\*, -127-3p,-324-3p) that share coordinated dysregulation of expression both in quiescent and in inflamed colonic mucosa of IBD patients. Six miRNAs displayed significantly distinct alteration of expression in non-inflamed colonic biopsies of UC and CD patients (mir-196b,-199a-3p,-199b-5p,-320a,-150,-223).

**Conclusions/Significance:** Our study supports miRNAs as crucial players in the onset and/or relapse of inflammation from quiescent mucosal tissues in IBD patients. It allows speculating a role for miRNAs as contributors to IBD susceptibility and suggests that some of the miRNA with altered expression in the quiescent mucosa of IBD patients may define miRNA signatures for UC and CD and help develop new diagnostic biomarkers.

**Citation:** Fasseu M, Tréton X, Guichard C, Pedrucci E, Cazals-Hatem D, et al. (2010) Identification of Restricted Subsets of Mature microRNA Abnormally Expressed in Inactive Colonic Mucosa of Patients with Inflammatory Bowel Disease. PLoS ONE 5(10): e13160. doi:10.1371/journal.pone.0013160

**Editor:** Guillaume Dalmaso, Emory University, United States of America

**Received:** June 21, 2010; **Accepted:** September 5, 2010; **Published:** October 5, 2010

**Copyright:** © 2010 Fasseu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** Institut National de la Santé et de la Recherche Médicale (Inserm) and in parts by grants from Association François Aupetit AFA, Assistance Publique-Hôpitaux de Paris, Ferring Laboratories, Ipsen Laboratories, Société Nationale Française de Gastro-entérologie (SNFGE), Association Française pour l'étude du foie (AFEF), and Programme National de Recherche en Hépatogastroentérologie. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** Funding by Ipsen Laboratories was only a small part of the doctoral fellowships dedicated to Xavier Tréton. It did not interfere with the study reported in the manuscript and does not alter the authors' adherence to all the PLoS ONE policies.

\* E-mail: andre.groyer@inserm.fr

9 These authors contributed equally to this work.

† These authors also contributed equally to this work.

## Introduction

Ulcerative Colitis (UC) and Crohn's Disease (CD) are two subphenotypes of inflammatory bowel disease (IBD) affecting the intestinal mucosa. UC and CD share similarities such as a chronic relapsing-remitting course and common extra-intestinal manifestations. However, several differences in localization (any part of the gastrointestinal tract -CD- or restricted to the colon -UC),

endoscopic appearance and histology support differences in underlying physiopathology.

The current understanding of IBD pathogenesis points out the interplay of genetic, epigenetic and environmental factors in the dysregulated immune response of the intestinal mucosa [1–3] where inappropriate control of innate and acquired immunity plays a major role [4].

Long term follow-up stressed that basal colonic lesions extend progressively in more than 50% of UC patients [5]. In CD

patients, ileal recurrence involving microscopically quiescent tissues at the time of ileo-colonic resection was reported to reach 73% at one year [6]. These observations suggest that quiescent mucosa of IBD patients display increased susceptibility to inflammation. In this connection, animal models (mice carrying intestinal epithelial cell-specific inactivation of genes involved in the unfolded protein response -XBP1, X-box Protein 1- or essential for embryonic development of the colon -HNF4, Hepatic Nuclear Factor 4) support the notion that epithelial cell dysfunction in the quiescent mucosa can trigger intestinal inflammation [7–8]. However the early epithelial disorders that, in pre-inflammatory states, confer susceptibility to uncontrolled mucosal inflammation remain poorly understood.

Strong evidence supports UC and CD as complex genetic disorders with significant overlap and mandates systematic approaches to identify causal molecular events. **First**, Genome Wide Association Scans (GWAS) [9–19] and candidate gene approach [20–25] led to the identification of more than 30 susceptibility loci for CD and UC and identified “IBD-specific” gene variants within these loci (eg. *CARD15*, *TNFSF15*, *IL23R*, *ATG16L1*, *IRGM*, *PTPN2*). **Otherwise**, genome-wide arrays and subtractive hybridization studies identified hundreds of mRNAs with altered expression in non-inflamed [26,27] and in inflamed [28–32] colonic biopsies obtained from UC and CD patients. This provided valuable insights into dysregulated gene expression associated with IBD. In this connection, we hypothesized that dysregulated microRNA (miRNA) gene expression and/or pre-/pre- miRNA maturation may contribute to IBD pathogenesis.

miRNAs are small (~18–24 nt), non-coding RNAs which, by base-pairing to complementary sequences in the 3'-UTR of selected mRNA targets, prevent protein synthesis either by translational suppression [33,34] or by degradation of their target mRNAs [35,36]. miRNAs are regulators of early development, cell fate determination, differentiation, proliferation, apoptosis [37–39] and dysregulation of their expression has been involved in various human diseases such as cancer [40–44], developmental abnormalities [45], muscular disorders [46] and inflammatory diseases [47–51].

In the present paper, **our first objective** was to pinpoint alterations in the pattern of miRNA expression in the non-inflamed colonic mucosa of UC and CD patients relative to that of healthy subjects. Indeed, such altered miRNA expression in the quiescent colonic mucosa of IBD patients may account for epithelial dysfunction in the absence of epithelial damage (eg. ulcerations) and sensitize the mucosa to severe inflammation and infiltration of immune cells. **Our second objective** was to search whether dysregulated expression of several miRNAs may be coordinated and thus contribute to IBD susceptibility.

## Results

In a first series of experiments, miRNA expression was quantified in right and left colon from healthy control subjects. Measuring the abundance of 321 mature human miRNA transcripts by real-time Q-PCR, preliminary analysis ( $2^{-\Delta\Delta CT}$ ) showed that right and left colon displayed similar patterns of miRNA expression, as exemplified for a subset of miRNAs in Table S1.

In a second series of experiments, miRNA expression was measured by real-time Q-PCR in biopsies from UC and CD patients (Table 1; quiescent and inflamed mucosal tissues, Figure S1). Overall, miRNA expression varied continuously from -11.06 to +20.31 -fold (quiescent and inflamed CD biopsies) and from -7.50 to +18.34 -fold (quiescent and inflamed UC biopsies) when

**Table 1.** Characteristics of patients with CD or UC.

	Ulcerative Colitis	Cronh's Disease
N° of patients	8	8
Male/Female	5/3	4/4
Age (* y)		
Mean	45.9	37.6
Range	33–57	20–58
Disease duration (y)		
Mean	10.5	8.8
Range	1–21	0.5–23
# Medications (%)		
5 ASA	6 (75)	2 (25)
CS	-	2 (25)
AZA	1 (13)	2 (25)
MTX, IFX	-	1 (13)
CS, 5 ASA	1 (13)	-
None	-	1 (13)

\*y, years;

#Medications : CS: steroids/5 ASA: 5 aminosalicylates/AZA: azathioprine/IFX: infliximab/MTX: methotrexate.

doi:10.1371/journal.pone.0013160.t001

compared to healthy control subjects. However, a careful inspection of the data showed that even under our strictly controlled (i) biopsy selection (Figure S2), (ii) RT and (iii) Q-PCR conditions, miRNA expression levels were variable among patients (Figure S3). Thus, in order to avoid false/erroneous classification of miRNAs as up- and down- regulated in mucosal biopsies of IBD patients, only miRNAs with alterations of expression that fitted stringent thresholds ( $2^{-\Delta\Delta CT} > 5$ -fold and  $2^{-\Delta\Delta CT} < 0.2$ -fold, respectively) were considered.


## miRNA expression is altered in both UC and CD

In order to check for specific modifications that may account for epithelial cell dysfunction in the quiescent colonic mucosa of IBD patients, we focused on biopsies scored grades 0 and 1 (both grades were observed in healthy controls and in quiescent UC and CD mucosa; Table S2). However, grades 2–4 (inflamed mucosa; see Figure S1) were also studied for comparison of both stages of the diseases.

According to our stringent criteria for the selection of miRNAs with altered expression, up- and down- regulations were balanced in UC (45.47% and 54.5%, respectively), whereas up-regulation was predominant (88.2%) in CD.

**UC.** 173 miRNAs were expressed above the level of detection ( $C_T < 35$ ). Of the 22 miRNAs that fit our stringent criteria, only 14 (7 up- and 7 down- regulated) exhibited significant differential expression when non-inflamed UC and healthy control tissues were compared ( $0.001 < p < 0.05$ ; non parametric Mann-Whitney test), (Table S3, Figure 1A). With respect to cut-off values and statistical significance the expression of 9 miRNAs was dysregulated in both quiescent and inflamed UC mucosa and that of 1 miRNAs was specifically dysregulated in quiescent UC mucosa (mir-196a).

**CD.** 204 miRNAs were expressed above the level of detection. Of the 33 miRNAs that fit our stringent criteria, only 23 (all up-regulated) exhibited significant differential expression when non-inflamed CD and healthy control tissues were compared



**Figure 1. Disease- and stage-specific alterations of miRNA expression.** miRNA expression was measured in non-inflamed and inflamed UC and CD tissues and computed vs. that measured in healthy controls. The total numbers of miRNAs that were underexpressed and overexpressed in non-inflamed (dark-colored ovals) or inflamed (light-colored ovals) IBD tissues, as well as those that were commonly altered in both states of the disease (intersect between light and dark-colored ovals) were determined. UC (A) or CD (B) tissues were considered independently. (C) miRNAs that were underexpressed and overexpressed in non-inflamed UC (dark-blue) or non-inflamed CD (dark-red), as well as those that were commonly altered in both diseases (intersect between ovals) were determined. Underexpressed miRNAs are underlined. Bolded characters, miRNA with statistically significant dysregulation of expression relative to healthy controls ( $p \leq 0.05$ ). doi:10.1371/journal.pone.0013160.g001

( $0.002 < p < 0.05$ ; non parametric Mann-Whitney test), (Table S4, Figure 1B). With respect to cut-off values and statistical significance the expression of 18 miRNAs were dysregulated in both quiescent and inflamed CD mucosa and that of 4 miRNAs were specifically dysregulated in quiescent CD mucosa (mir-9\*, mir-30a\*, mir-30c, mir-223).

Finally, taking into account cut-off values and statistical significance, we also noticed alterations in miRNA expression specific to inflamed UC or CD tissues (4 and 5 miRNAs, respectively) (Figure 1A, B).

### Common and specific alterations in miRNA expression in UC and CD

With respect to cut-off values and statistical significance 8 miRNAs shared common altered expression in non-inflamed CD and in non-inflamed UC (Figure 1C, Table S5), of which 6 (all but mir-30c, and mir-196a) were also overexpressed both in inflamed UC and in inflamed CD biopsies.

On the other hand, the expression of 6 miRNAs was statistically different in non-inflamed colonic biopsies of UC and CD patients (mir-150,  $p = 0.0273$ ; mir-196b,  $p = 0.0472$ ; mir-199a-3p,  $p = 0.0472$ ; mir-199b-5p,  $p = 0.0283$ ; mir-223,  $p = 0.0357$  and mir-320a,  $p = 0.0163$ ; non-parametric Mann-Whitney test) (Figure 2). These miRNAs, and an additional selection of 9 miRNAs (selected in an unsupervised manner using the GenePattern “ComparativeMarkerSelection” module) (Owing to patent pending the identity of these miRNA is not disclosed in the manuscript) were tested for their ability to discriminate between UC and CD. Classification was performed with a supervised algorithm (GenePattern “KNNXValidation” module). Based on the clinical classification of our panel of patients as UC or CD, the

selection of 15 miRNAs was able to predict 15/16 patients in their true class (Table 2).


Altogether, these data unambiguously show that altered miRNA expression pre-exists in non-inflamed UC and CD mucosa.

### Concerted regulation of miRNA expression in UC and CD

We then sought whether the altered levels of miRNA noticed in both quiescent UC and CD colonic mucosa could be accounted for by coordinated regulation(s) of miRNA expression. *In silico* clustering was achieved in an unsupervised manner using a K-Means algorithm, the expression data being partitioned into 20 distinct computational clusters. Interestingly, 7/8 miRNAs overexpressed both in non-inflamed UC and CD tissues (mir-26a, mir-29a, mir-29b, mir-30c, mir-126\*, mir-127-3p, mir-324-3p), localized on different chromosomes, were assigned to a single computational cluster (cluster #7) when examining UC data, and to two such clusters (cluster #7: mir-26a, mir-30c, mir-127-3p, mir-324-3p and cluster #13: mir-29a, mir-29b, mir-126\*) when CD data were inspected (Table 3). Moreover, five of these miRNAs (mir-26a, mir-29b, mir-126\*, mir-127-3p, mir-324-3p) were also assigned to a single computational cluster when inflamed UC (cluster #7) and CD (cluster #13) data were classified. This suggested common regulation of expression for mir-26a, mir-29b, mir-126\*, mir-127-3p and mir-324-3p.

### Chromosomal localization of miRNA genes with altered expression

The chromosomal distribution of miRNA genes with altered expression in UC and CD mucosa was not even. Indeed, 9 chromosomes (1, 5, 9, 11, 14, 15, 17, 19 and X) housed  $\geq 4$  and up to 12 miRNA genes with dysregulated expression (overall:  $\sim 70\%$



**Figure 2. miRNAs with differentially altered expression in non-inflamed UC and CD tissues : Box-whisker plot analysis.** miRNA expression was measured in non-inflamed colonic mucosa obtained from UC and CD patients (8 patients/IBD) and computed vs. that measured in healthy controls. Data corresponding to 6 miRNAs (mir-150, mir-196b, mir-199a-3p, mir-199b-5p, mir-223 and mir-320a) with statistically different alteration of expression in UC and CD mucosal tissues are presented as box-whisker plots [78] (box, 25–75%; whisker, 10–90%; line, median);  $p < 0.05$ . doi:10.1371/journal.pone.0013160.g002

of such miRNAs genes) (Table S6, Figure S4). The chromosomal loci where miRNA genes with dysregulated expression are localized encompass either one, two (miRNA duplexes) or more (miRNA clusters) distinct miRNA genes.

Interestingly, it could be observed that several miRNAs mapped within acknowledged IBD susceptibility loci (IBD-2, 3, 5 and 6), or colocalized with genetic variations identified in several GWAS studies that (i) account for part of the overall genetic susceptibility to CD and (ii) contribute to UC pathogenesis (Figure S5, Table S7). None mapped with IBD susceptibility loci 1, 4, 7, 8 and 9.

Otherwise, one chromosomal miRNA cluster (on chromosome 14q32.31) and several miRNA duplexes (6q13, 7q32.3, 9q34.11–q34.3, 15q26.1; 17p13.1–p13.3, 22q11.21, Xq26.2) were identified that map on chromosomal regions that have not been previously reported as IBD-susceptibility loci (Figure S5, Table 4). Interestingly, in the majority of loci, alterations of miRNA expression were observed in quiescent UC and CD tissues.

#### Alteration of miRNA expression: *in silico* characterization of target transcripts

Identification of a subset of 8 miRNAs that share common regulated overexpression in both UC and CD (*see* Table S5) could represent the first step towards the identification of regulatory networks, the dysregulation of which could be involved in the pathophysiology of IBD. *In silico*, 4094 genes (372 strictly down-regulated genes) stand as putative targets for these miRNAs.

Exploring the molecular functions associated to these gene products using The Gene Ontology, GeneCards and GeneNote data bases, we found associations to several biological processes (Figure 3). These include (i) cell proliferation (Cyclins D1, D2 and E1, PCNA, CDKs 6 and 8, GADD45A, RB1), (ii) apoptosis (BCL2, Caspase 2, C/EBP  $\beta$ ,  $\gamma$ , DAPK, FOXO3, PTEN), (iii) autophagy (ATG 4a, 5 and 9a, Beclin-1, CDKN1B, IFN $\gamma$ ), (iv) extracellular matrix organization, cell adhesion and cell surface marker gene expression (COL(1,11,12,15,16)A1, Integrin- $\alpha_{1,2,3,5}$ ,



**Table 2.** Achievement of patient's class (UC or CD) prediction using the selection of 15 miRNAs.

Patient	True Class		Predicted Class	Confidence	Correct ?	
	Initial Diagnostic	Reassessment After Clinical Follow-up			Relative to Initial Diagnostic	After Clinical Follow-up/Reassessment
CD_Quiescent_28	Cd	Not modified	Uc	1	false	
CD_Quiescent_102	Cd	Not modified	Cd	1	true	
CD_Quiescent_111	Cd	Not modified	Cd	1	true	
CD_Quiescent_120	Cd	Not modified	Cd	1	true	
CD_Quiescent_130	Cd	Not modified	Cd	0,7894	true	
CD_Quiescent_137	Cd	Not modified	Cd	1	true	
CD_Quiescent_158	Cd	Not modified	Cd	1	true	
CD_Quiescent_160	Cd	Not modified	Cd	1	true	
UC_Quiescent_107	Uc	Not modified	Uc	1	true	
UC_Quiescent_125	Uc	Not modified	Uc	0,8144	true	
UC_Quiescent_121	Uc	Not modified	Uc	1	true	
UC_Quiescent_114	Uc	Not modified	Uc	0,5339	true	
UC_Quiescent_109	Uc	Not modified	Uc	0,5508	true	
<b>UC_Quiescent_13</b>	<b>Uc</b>	<b>Cd</b>	<b>Cd</b>	<b>0,6229</b>	<b>false</b>	<b>true</b>
UC_Quiescent_15	Uc	Not modified	Uc	0,6415	true	
UC_Quiescent_132	Uc	Not modified	Uc	0,5176	true	

The 6 miRNAs that displayed significantly distinct alteration of expression in non-inflamed colonic biopsies of UC and CD patients and 9 additional miRNAs, which were selected in an unsupervised manner making use of the GenePattern "ComparativeMarkerSelection" module, were tested for their putative use as "biomarkers". The test was carried out using the "KNNValidation" module computed on-line from the GenePattern server. **Of note**, patient "UC\_Quiescent\_13", initially classified as UC on the basis of clinical criteria, was predicted as CD using our selection of 15 miRNAs. Interestingly its clinical follow-up for several years led to the reassessment of its clinical classification as CD.

doi:10.1371/journal.pone.0013160.t002

**Table 3.** Concerted regulation of expression of miRNAs in non-inflamed and inflamed CD and UC tissues.

Overexpressed miRNA			
UC		CD	
Non-inflamed	Inflamed	Non-inflamed	Inflamed
<b>Cluster #7 :</b>	<b>Cluster #7 :</b>	<b>Cluster #7 :</b>	<b>Cluster #13 :</b>
mir-15a	mir-7	mir-7	<b>mir-26a</b>
<b>mir-26a</b>	<b>mir-26a</b>	<b>mir-26a</b>	<b>mir-29b</b>
mir-29a	mir-29a	mir-30b	<b>mir-126*</b>
<b>mir-29b</b>	<b>mir-29b</b>	mir-30c	mir-155
mir-30c	mir-31	<b>mir-127-3p</b>	<b>mir-127-3p</b>
<b>mir-126*</b>	<b>mir-126*</b>	mir-155	mir-185
<b>mir-127-3p</b>	<b>mir-127-3p</b>	mir-223	mir-196a
<b>mir-324-3p</b>	mir-135b	<b>mir-324-3p</b>	<b>mir-324-3p</b>
	<b>mir-324-3p</b>		mir-378
		<b>Cluster #13 :</b>	
		mir-29a	
		<b>mir-29b</b>	
		<b>mir-126*</b>	
		mir-196a	

Alterations in miRNA expression (8 UC, 8 CD patients) were clustered using a K-Means algorithm (computed on-line on the GenePattern server), independently in each IBD and for each state of the disease. Clusters that encompass several miRNAs with similarly up-regulated expression are highlighted (bold characters).

doi:10.1371/journal.pone.0013160.t003

$\beta_{1,3}$ , Laminin  $\gamma_1$ , MMPs 13 and 16, Keratin 5, NCAM1), (v) oxidative stress (GPX4, OXR1, OSXR1), (vi) the unfolded protein response (HSPA5, HSPA2, SERP1, XBP-1, EIF2AK3, ETF1) (vii) innate and adaptive immunity (IL1A, IL10, IL1R1, IL6R, IRAK2, p40<sup>phox</sup>, TLR10, CXCL2, 12 and 14, CXCR4, NFATC3 and C4, PREX1). In addition, several of these genes are acknowledged IBD-susceptibility genes or are localized at replicated risk loci identified by GWAS (eg. ATG16L1, IL10, IL12B, JAK2, ARPC2, PTGER4, ZNF365, NKX2-3, PTPN2, PTPN22, C11orf30, ORM DL3, STAT3 (Table S8).

## Discussion

In the present study, we have addressed the question of whether altered miRNA expression in quiescent UC and CD mucosa may be relevant to IBD pathogenesis. Our data allowed two major conclusions.

**First.** Alteration of miRNA expression was not confined to inflamed (grades 2–4), but preexisted in non-inflamed (grades 0 and 1) mucosa. Applying strictly controlled RT and real-time Q-PCR protocols and stringent cut-off values (>5-fold or <0.2-fold vs. healthy individuals), we identified 14 and 23 miRNAs with dysregulated expression in non-inflamed UC and CD biopsies, respectively, of which 8 were similarly dysregulated both in non-inflamed UC and CD biopsies. Our observation that mir-26a and 29a are up-regulated in quiescent UC mucosa has also been reported by Wu *et al.* [51]. In contrast, the other miRNAs (9/10, mir-629 was not tested in our screen) which were found to be up- (eg. mir-21, mir-126 and Let-7f) or down- (eg. mir-19b) regulated in [51] displayed only slight alterations in relative expression that did not match the stringent selection criteria we applied in our study. This suggests (i) that the discrepancies between both studies may

**Table 4.** Compilation of the sub-chromosomal regions where two or more miRNA genes with altered expression colocalize.

Chromosome	miRNA		Alteration of Expression			Duplex/Cluster
	Gene_Id	Locus	IBD_Type	Disease state	+/-	
6	30c-2	6q13	CD/UC	Quiescent/Quiescent	+	miRNA Duplex
	30a*	6q13	CD	Quiescent	+	
7	29a	7q.32.3	CD/UC	Both/Both	+	miRNA Duplex
	29b-2	7q.32.3	CD/UC		+	
9	199b-5p	9q34.11	UC	Both	-	miRNA Duplex
	126	9q34.3	CD	Inflamed	+	
	126*	9q34.3	CD/UC	Both/Both	+	
14	127-3p	14q32.31	CD/UC	Both/Both	+	miRNA Cluster
	370	14q32.31	UC	Both	-	
	382	14q32.31	UC	Inflamed	+	
15	7-2	15q26.1	UC	Inflamed	+	miRNA Duplex
	9-3	15q26.1	CD	Inflamed	+	
17	22	17p13.3	CD	Both	+	miRNA Duplex
	324-3p	17p13.1	CD/UC	Both/Both	+	
22	185	22q11.21	CD	Both	+	miRNA Duplex
	130b	22q11.21	CD	Inflamed	-	
X	106a	Xq26.2	CD	Both	+	miRNA Duplex
	20b	Xq26.2	CD	Inflamed	+	

Compilation of chromosomes and bands where colocalize 2 (miRNA Duplex) or more (miRNA Cluster) miRNA genes with altered expression relative to healthy controls in UC or CD tissues. Gene\_Id, miRNA gene identification number; Locus, chromosomal band where the miRNA gene is localized; Quiescent, non-inflamed; Both, non-inflamed and inflamed; +/-, +: overexpression; -: underexpression.  
doi:10.1371/journal.pone.0013160.t004

be explained either by the differential sensitivity of the methods used for initial screening (microarray *vs.* real-time Q-PCR) and/or rather by the drastic cut-off value (>5-fold or <0.2-fold) we used to state altered miRNA expression in the present study and (ii) that the overlap in the alteration of miRNA expression observed in our study and in that reported by Wu *et al.* [51] may not have occurred only by chance. As far as we are aware, alteration of miRNA expression in non-inflamed CD colonic biopsies has not yet been reported.

Importantly, despite (i) the choice of a drastic cut-off that takes into account the variability in miRNA expression between IBD patients and (ii) the limited number of subjects kept for analysis in the present study, we could select miRNAs highly and significantly dysregulated in IBD relative to healthy controls. Interestingly, comparison of non-inflamed to inflamed tissues showed significant overlap in the alteration pattern of miRNA expression both in CD patients (this study) and UC (this study, [51]).


Altogether, these results support the notion that dysregulation of miRNA expression pre-exists in the quiescent colonic mucosa of UC and CD patients and may play a key role in the sensitization of the quiescent mucosa to environmental factors and/or to IBD inducers (*ie.* commensal flora), and *in fine* the onset and/or relapse of inflammation. Furthermore, they suggest that quiescent UC and CD mucosa already has distinct miRNA signatures which are not associated with significant variations in cellular contexts. Indeed, the quiescent colonic mucosa of IBD patients and that of healthy subjects were almost similar (grades 0 or 1 in both cases).

Since significant overlap was observed in the alteration of miRNA expression in quiescent UC and CD mucosa, our results also imply that several common molecular mechanisms may underlie the UC and CD pathogenic processes. Furthermore,

alteration of miRNA expression in quiescent IBD tissues is consistent with the notion that genetic variants that result in differential gene expression (*eg.* that of regulatory molecules such as miRNAs) as well as mutations in the open reading frame are expected to contribute to multifaceted diseases.

In this connection, one major drawback in investigating the dysregulation of miRNAs and of protein-coding genes expression in IBD tissues is related to cell type variations between samples (*eg.* inflamed *vs.* quiescent mucosa and normal healthy tissue). Indeed, inflamed mucosal tissue is characterized by a decreased number of epithelial cells, concomitant with an increased infiltration of inflammatory cells. This bias was taken into account in some genome wide cDNA microarray studies [26] but not in others [31]. For instance, decreased MICA (a gene expressed in intestinal epithelial cells) transcript expression was reported in inflamed CD [31] whereas flow cytometry and immuno-histochemistry identified strong MICA overexpression in intestinal epithelial cells of macroscopically involved areas of CD patients [52]. Similarly, it could be anticipated that the decreased level of mir-192 expression in inflamed mucosa of UC patients [51] may depend on cell-type heterogeneity between non-inflamed and inflamed mucosal tissues rather than on decreased gene expression (of note, in our study the slight decrease in mir-192 expression did not match our selection criteria in inflamed UC mucosa). Thus, the increase in MIP2 $\alpha$  expression observed in [51] could be miRNA-independent and accounted for by increased TNF $\alpha$  secretion by immune infiltrating cells.

Finally, starting with a wide screen of 321 miRNAs, we could define (i) a selection of 8 miRNAs relevant in defining quiescent IBD *vs.* healthy mucosa and (ii) a distinct subset of 15 miRNAs (Patent pending) that allows discriminating between non-inflamed



**Figure 3. Alteration of miRNA expression in the colonic mucosa of UC and CD patients: *in silico* characterization of target transcripts.** The exhaustive list of genes which are putatively targeted by the subset of 8 miRNAs that share common dysregulated expression both in quiescent UC and in quiescent CD was downloaded from the PITA catalog of predicted human microRNA targets ([http://genie.weizmann.ac.il/pubs/mir07/mir07\\_data.html](http://genie.weizmann.ac.il/pubs/mir07/mir07_data.html)). The algorithm makes use of the parameter-free model for miRNA-target interaction described by Kertesz *et al.* [75]. The total number of genes involved in each single biological process is computed. Strict down regulation (light purple) stands for genes, the 3'-UTR of which interacts only with up-regulated miRNA(s). doi:10.1371/journal.pone.0013160.g003

UC and CD colonic mucosa and may define specific biomarkers relevant for UC and CD. Indeed on the basis of our panel of 16 patients, this selection of 15 miRNAs was able to predict 15/16 patients (94%) as UC or CD correctly. Such biomarkers may prove helpful as diagnostic tools of minimal invasivity (*eg.* for pediatric patients, incomplete colonoscopy) and as guidelines for surgical decisions. It can also be anticipated that miRNA signatures could be associated with different IBD profiles as prognostic biomarkers. This is out of the scope of the present study and deserves further studies on a larger cohort of patients.

**Second.** miRNAs play a major role in regulating coding-gene expression at the transcript and/or translational levels [34,36]. In this connection, we would like to emphasize that our study is the first one that reports the mapping of several miRNA genes with altered expression in quiescent UC and CD mucosa (*i*) at acknowledged IBD loci [53–55] or (*ii*) at loci conclusively associated with CD [11,16] } or UC [12,13,19] by GWAS studies. In this connection, we should like to emphasize that the co-localization of miRNA genes with dysregulated expression at chromosomal loci associated with IBD susceptibility does not occur only by chance. Indeed, our computations show that 1 miRNA gene (out of 321 tested) would be expected to be localized by chance in the vicinity of the 50 loci reported in [11,12,16–19] where 14 miRNA genes (14-fold more) with altered expression in quiescent UC and CD tissues map. In addition, even if 8 miRNA genes could map by chance within IBD susceptibility loci 1, 4, 7, 8 and 9, no miRNA genes with altered expression in quiescent UC and CD tissues were localized in these chromosomal regions

(although they encompass a total of 18 miRNA genes, the expression of which is not altered in IBD).

On this basis, we speculate that in addition to mutational events, IBD susceptibility might result from dysregulated miRNA expression in intestinal mucosa and to subsequent alteration of miRNA-dependent regulation of gene expression; consistent with the notion that not only allele variation, but also the alteration of regulatory processes that result in differential gene expression may contribute to multifaceted diseases.

Furthermore, our study characterizes band 14q32.31 as a cluster of 3 miRNA genes with altered expression in IBD. With the exception of mir-382, these miRNAs display altered expression in quiescent UC (mir-127-3p, mir-370) or in quiescent CD (mir-127-3p) mucosa. These miRNA genes are intergenic and constitute at least two distinct transcription units (mir-127 and mir-370). Alteration of miRNA expression within this sub-chromosomal region does not result from the overall chromosomal environment since (*i*) only the expression of 3 (UC) and 1 (CD) miRNAs was altered out of 38 localized within a DNA stretch of 44.74 kbp at 14q32.31, (*ii*) expression was either increased (mir-127-3p, CD/UC; mir-382, UC) or decreased (mir-370, UC) and (*iii*) expression was altered either in non-inflamed or in inflamed or in both states of the diseases. We speculate band 14q32.31 may represent a new, yet undefined IBD-susceptibility locus; this remains to be established and will be the subject of future studies.

Finally, the tight coordinated regulation of mir-26a, mir-29b, mir-126\*, mir-127-3p and mir-324-3p (which genes are widespread on several chromosomes) in non-inflamed UC and CD



mucosa also suggests that alteration of miRNA expression do contribute to the physiopathology of IBD. Interestingly, such concerted regulation of expression correlates with related biological functions. For instance, these miRNAs have been demonstrated to play roles either in cell cycle regulation, or in tumorigenesis in a broad spectrum of solid tumors (mir-26a, mir-29b, mir-127-3p and mir-324) [56–61], in the regulation of epithelial-mesenchymal transition and invasiveness (mir-126\*) [62,63] or in the control of apoptosis (mir-29b and mir-126\*) [64,65], in line with the higher than spontaneous occurrence of colorectal cancer (5–10%) in IBD patients. Of note, a recent study has reported that the mir-29 family of miRNAs regulates intestinal membrane permeability [66]. This observation should be connected with the increased gut permeability observed in IBD patients [67].

*In silico* studies emphasized that the transcripts targeted by the 8 miRNAs which share common overexpression in the quiescent colonic mucosa of both UC and CD patients correspond to genes that are involved/implicated in several cellular processes (*eg.* proliferation, apoptosis, autophagy, extracellular matrix organization, cell surface marker gene expression, oxidative stress, unfolded protein response, innate and adaptive immunity). Several of these genes stand as acknowledged IBD susceptibility genes or as genes of interest localized at convincingly replicated risk loci identified by GWAS (*eg.* ATG16L1, IL10, IL12B, JAK2, ARPC2, PTGER4, ZNF365, NKX2-3, PTPN2, PTPN22, C11orf30, ORMDL3, STAT3). However, an exhaustive identification of the genes targeted by UC- and/or CD- associated miRNAs (*eg.* common to or distinct between UC and CD), the demonstration of their actual regulation by miRNAs and the investigation of their influence on intestinal inflammation in experimental models of colitis is far beyond the scope of this paper and will be the subject of future studies.

Our study supports miRNAs as crucial players in the onset and/or relapse of inflammation from quiescent mucosal tissues in UC and CD patients. It further highlights their putative role as contributors to IBD susceptibility and thus will help unravel the mechanisms (either distinct or shared between UC and CD) involved in relapsing (*eg.* identification of key targets and of gene networks). Finally, they may help develop new biomarkers to distinguish UC and CD at early stages.

## Materials and Methods

### IBD patients and controls

Colonic pinch biopsies were obtained in the course of endoscopic examination of patients with mild to severe CD and UC and of healthy control subjects undergoing screening colonoscopies (Table S2 for clinical details). Colonic biopsies were punctured from 24 CD, 18 UC and 19 healthy controls (*see* Figure S2). However, for the reasons outlined below (*see* paragraphs “Histopathological analyses” and “RNA isolation”) and in Figure S2, the biopsies collected from some patients were not included in the study. Overall, expression of mature miRNAs was studied in inactive colonic mucosa of 8 patients with UC, 8 patients with CD and in 10 healthy control mucosa.

The diagnosis of UC and CD adhered to the criteria given by Lennard-Jones [68]. Clinical disease activity for CD and UC was assessed according to the Harvey-Bradshaw [69] and to the Colitis Activity (CAI) [70] indexes, respectively. In each IBD patient, endoscopically non-inflamed and inflamed areas of colonic tissue were punctured (5 biopsies/area). Non-inflamed and inflamed areas for biopsy collection were separated by more than 20 cm along the colon. Three biopsies from each area were allocated for

immediate RNAlater™ immersion then snap frozen and stored in liquid nitrogen, and two were set apart for histopathological examination. In healthy controls, 5 biopsies were punctured both in right and left colon and processed as above. The protocol was approved by the local Ethic Committee (Comité de Protection des Personnes -CPP- Ile de France IV n°2009/17 and AFFSSAPS D91534-80) and written informed consent was obtained from all patients.

### Histopathological analyses

Biopsies were routinely stained with haematoxylin and eosin. Histological assessments of mucosal damage and inflammatory cells infiltration were graded by the same expert gastrointestinal pathologist (DCH) using a score previously validated to characterize the colonic involvement of both UC and CD [71]. Grades were as follows: 0, no evidence of inflammation (normal mucosa); 1, oedema and mild infiltration in the *lamina propria*; 2, crypt abscess and inflammation in the *lamina propria*; 3, severe inflammation with destructive crypt abscess and 4, severe inflammation with active ulceration. Grades 0–1 were considered as quiescent (or non-inflamed) mucosa. Grades 2–4 corresponded to various degrees of inflammation of the mucosa and were considered as active disease (Figure S1). Alterations in miRNA expression were studied following this histological dichotomy (0–1 *vs.* 2–4). IBD patients selected for miRNA analysis had both histologically assessed quiescent and inflammatory samples. 7 CD patients and 3 UC patients were excluded because their endoscopically quiescent colonic mucosa was classified as histologically active. 1 control patient with lymphocytic colitis was excluded (Figure S2).

### RNA Isolation

Total RNA was extracted with TRIzol® Reagent (Invitrogen) then quantified using a ND-1000 NanoDrop spectrophotometer (NanoDrop Technologies) and purity/integrity was assessed using disposable RNA chips (Agilent RNA 6000 Nano LabChip kit) and an Agilent 2100 Bioanalyzer (Agilent Technologies, Waldbrunn, Germany). Only RNA preparations with RIN $\geq$ 7 were further processed for analysis of miRNA expression. Nine CD, 7 UC and 8 controls with RNA preparations of insufficient purity (RIN $<$ 7) were excluded. Finally 8 CD, 8 UC and 10 controls with stringent homogeneity in histological assessment and RNA quality were selected for analysis (Figure S2).

### Reverse-Transcription and Real-Time Q-PCR

The Human Early Access Release Kit (based on miRBase v 9.2; TaqMan® MicroRNA Assay; Applied Biosystems) designed to quantify 321 mature human miRNAs was used. cDNA was generated from 10 ng of total RNA using miRNA-specific stem-loop RT primers. Real-Time Q-PCR assays were performed according to the manufacturer’s instructions using aliquots of cDNA equivalent to  $\sim$ 1.3 ng of total RNA and were run in a Light Cycler 480 (Roche Diagnostics).

**Normalization of Real-Time Q-PCR results.** Several RNAs (U6, U24, U48 and S18) were tested as putative standards and U6 (an ubiquitous small nuclear RNA) (Primer for U6 were included in the TaqMan® MicroRNA Assay) was found the most reliable. Expression of miRNAs was computed relative to that of U6 and a comparative threshold cycle method ( $2^{-\Delta\Delta CT}$ ) [72] was used to compare non-inflamed and inflamed IBD tissues with healthy controls. Since the abundance of mature miRNA transcripts was expressed relative to that of the reference gene U6, we have checked that PCR efficiencies were identical for test

(miRNAs) and reference (U6) transcripts, so that the comparison be accurate (see the MIQE guidelines; [73]).

CT, the fractional cycle number at which the amount of amplified target reaches a fixed threshold, was determined (default threshold settings were used in all instances). The cycle number above which the CT was considered as a false positive (cycle cut-off point) was set up at 35, as already argued in the literature dealing with limits of detection in Real-Time Quantitative- RT-PCR [74] (reviewed in [73]).  $-\Delta\Delta CT$  was calculated as follows:

$$-\Delta\Delta CT = -(CT_{IBD} - \Delta CT_{healthycontrol})$$

where

$$\Delta CT_{healthycontrol} = (CT_{healthycontrol} - CT_{U6})$$

And

$$\Delta CT_{IBD} = (CT_{IBD} - CT_{U6})$$

**Determination of cut-off values for miRNA over- and under-expression.** Relative miRNA expressions ( $2^{-\Delta\Delta CT}$ ) were computed as their log transformed ( $10 \times \log_{10}$ ) values (after such computation up- and down-regulations were expressed as positive and negative values, respectively), and their means and standard deviations ( $SD_{miRNA}$ ) were calculated independently for every miRNA, in each IBD at each stage of the disease. Box-whisker plots analysis of  $SD_{miRNA}$  pointed highly dispersed values among patients (Figure S3). Overall, when the data gathered from the two series of patients were considered (8 UC, 8 CD; non-inflamed and inflamed areas of colonic tissues), a mean value of  $6.3 \pm 1.4$  ( $mean_{Disp} \pm SD_{Disp}$ ) was calculated for the  $SD_{miRNA}$  values. Given such variation in relative miRNA expression, only those with  $mean\ 10 \times \log_{10} 2^{-\Delta\Delta CT} > 7$  and  $< -7$  ( $\pm |mean_{Disp} + 0.5 SD_{Disp}|$ ) were considered as up- ( $2^{-\Delta\Delta CT} > 5$ -fold) and down- ( $2^{-\Delta\Delta CT} < 0.2$ -fold) regulated relative to healthy.

### In silico prediction of miRNA targets

Exhaustive human miRNA targets were predicted using a parameter-free model for miRNA-target interaction. This model computes the difference between the free energy gained from the formation of the miRNA-target duplex ( $\Delta G_{duplex}$ ) and the energetic cost of unpairing the target (and proximal flanking sequences) to make it accessible to the miRNA ( $\Delta G_{open}$ ) [75].

We made use of the PITA catalog of predicted human microRNA targets ([http://genie.weizmann.ac.il/pubs/mir07/mir07\\_data.html](http://genie.weizmann.ac.il/pubs/mir07/mir07_data.html)). The seed parameter settings described in Kertesz *et al.* [75] were followed: seeds of 8 bp in length, beginning at position 2 of the miRNA were chosen, seed conservation being set at 0.9. No mismatches or loops were allowed, but a single G:U wobble was permitted. In genes missing a 3' UTR annotation, 800 bp downstream of the annotated end of the coding sequence were used as the predicted 3' UTR. Flanks of 3 and 15 bp upstream and downstream the miRNA target, respectively, were considered in the computation of  $\Delta G_{open}$ .

In some instances (mir-126\*) predictions from the miRBase database (miRBase Targets Release Version v5; [http://microrna.sanger.ac.uk/cgi-bin/targets/v5/mirna.pl?genome\\_id=2964](http://microrna.sanger.ac.uk/cgi-bin/targets/v5/mirna.pl?genome_id=2964)) were downloaded. These predictions combine the miRanda algorithm and the conservation of miRNA binding sites in orthologous transcripts from at least two species (<http://microrna.sanger.ac.uk/targets/v5/info.html> for details) [76].

### Biological functions of the *in silico* predicted miRNA targets

We made use of the Gene Ontology (<http://www.geneontology.org>), GeneCards (<http://www.genecards.org/>) and GeneNote ([http://bioinfo2.weizmann.ac.il/cgi-bin/genenote/home\\_page.pl](http://bioinfo2.weizmann.ac.il/cgi-bin/genenote/home_page.pl)) databases to document the biological functions of the genes that were predicted to be targeted by miRNAs with altered expression in quiescent UC and CD tissues (see Table S8).

### Statistical analysis

Unpaired groups of values were compared according to the non-parametric Mann-Whitney test. Statistical significance was set at  $p \leq 0.05$ .

miRNA which shared closely related expression patterns were grouped according to K-means clustering [77] computed on line from the GenePattern Server. The specified number of clusters was set at 20.

When supervised class (UC or CD) prediction of individual patient's data was tested, we used a K Nearest Neighbors Classification algorithm with Leave-One-Out Cross-Validation (GenePattern "KNNXValidation" module). The class predictor was uniquely defined by the initial set of patients and marker miRNAs. The classifications were tested in leave-one-out cross-validation mode by iteratively leaving one sample out, training a classification on the remaining data and testing on the left out sample.

### Supporting Information

**Figure S1** Histological grading of disease activity in colonic biopsies. Hematoxylin and eosin staining of biopsies from non-inflamed and inflamed colonic mucosa (see Materials and Methods for details on histological grading). Note the progressive loss of intestinal epithelium with increasing grade of the disease (2–4) and the concomitant increase in the severity of inflammation/infiltration. Magnification,  $\times 100$ .  
Found at: doi:10.1371/journal.pone.0013160.s001 (0.35 MB TIF)

**Figure S2** Flow chart of sample selection. In order to exclude any bias in homogeneity among samples, biopsies of patients with endoscopically quiescent, but histologically active colonic mucosa were excluded. The histological dichotomy (grades 0–1 vs. 2–4) was strictly followed to study the alteration in miRNA gene expression. Similarly, 1 control patient with lymphocytic colitis was excluded. In all cases, RNA preparations of low integrity ( $RIN < 7$ ) were discarded.  
Found at: doi:10.1371/journal.pone.0013160.s002 (0.09 MB TIF)

**Figure S3** Alteration of miRNA gene expression in non-inflamed and inflamed UC and CD tissues: Box-whisker plot analysis of standard deviations. miRNA expression was measured in non-inflamed and inflamed colonic mucosa obtained from patients with UC and CD (8 patients/IBD) and computed vs. that measured in healthy controls. The mean and standard deviation ( $SD_{miRNA}$ ) of relative miRNA expression were then calculated for every miRNA, independently in each IBD for each state of the disease.  $SD_{miRNA}$  were then plotted as box-whisker plots (box, 25–75%; whisker, 10–90%; line, median) (1). 1 Tukey, J. W. (1977) in *Exploratory Data Analysis* (Addison-Wesley, Reading, MA), pp. 39–43.  
Found at: doi:10.1371/journal.pone.0013160.s003 (0.06 MB TIF)

**Figure S4** Overview of the chromosomal distribution of miRNA genes with altered expression in IBD tissues: The total number of miRNA genes with altered expression was determined by

chromosome. Negative and positive ordinates stand of over and under -expression, respectively.

Found at: doi:10.1371/journal.pone.0013160.s004 (0.10 MB TIF)

**Figure S5** Alteration of miRNA gene expression in IBD tissues: sub-chromosomal localization of the affected loci. Chromosomal bands where 2 (arrowheads) or more (squares) miRNA genes with altered expression colocalize are shown. Grey and light-red symbols represent loci where IBD susceptibility has yet been demonstrated by genetic means and previously unidentified loci, respectively.

Found at: doi:10.1371/journal.pone.0013160.s005 (0.12 MB TIF)

**Table S1** miRNA expression in left and right colon of healthy individuals. Relative miRNA expression ( $10 \times \log_{10} 2^{-\Delta\Delta CT}$ ; see Materials and Methods) was calculated in the right and left colons independently. Note that miRNA expression was similar in both segments of the colon.

Found at: doi:10.1371/journal.pone.0013160.s006 (0.02 MB XLS)

**Table S2** Characteristics of patients with CD or UC and of healthy control individuals. \* Sex: F : female/M : male; + disease location: C: colon/IC: ileocolonic/C+AP: colon and anoperineal lesions/R: right colon/S: sigmoid colon/LC: left colon; # Current treatment : CS: steroids/5 ASA: 5 aminosalicylates/AZA: azathioprine/IFX: infliximab/MTX: methotrexate.

Found at: doi:10.1371/journal.pone.0013160.s007 (0.01 MB XLSX)

**Table S3** Alterations of miRNA expression in UC patients. Relative miRNA expression was computed vs. that measured in healthy controls and expressed as  $10 \times \log_{10} 2^{-\Delta\Delta CT}$ . Are only listed the miRNAs with relative expressions  $>7$  or  $<-7$  in non-inflamed UC tissues. When adequate, alteration of expression in inflamed UC is also mentioned. Access\_N°, MIMAT identification number; Mean  $\pm$  Sem (5–8 patients). Statistical significance (p values) was calculated relative to healthy control tissue using the non-parametric Mann-Whitney test. Bolded, miRNA with statistically significant dysregulation of expression in both quiescent and inflamed UC.

Found at: doi:10.1371/journal.pone.0013160.s008 (0.03 MB XLS)

**Table S4** Alterations of miRNA expression in CD patients. Relative miRNA expression was computed vs. that measured in healthy controls and expressed as  $10 \times \log_{10} 2^{-\Delta\Delta CT}$ . Are only listed the miRNAs with relative expressions  $>7$  or  $<-7$  in non-inflamed CD tissues. When adequate, alteration of expression in inflamed CD is also mentioned. Access\_N°, MIMAT identification number; Mean  $\pm$  Sem (5–8 patients). Statistical significance (p values) was calculated relative to healthy control tissue using the non-parametric Mann-Whitney test. Bolded, miRNA with statistically significant dysregulation of expression both in quiescent and in inflamed CD.

Found at: doi:10.1371/journal.pone.0013160.s009 (0.04 MB XLS)

**Table S5** Shared alterations of miRNA expression in UC and CD patients. Relative miRNA expression was computed vs. that measured in healthy controls. miRNA with shared and significant

overexpression ( $10 \times \log_{10} 2^{-\Delta\Delta CT} > 7$ ) both in non-inflamed UC and in non-inflamed CD tissues are listed. Access\_N°, MIMAT identification number; Mean  $\pm$  Sem (5–8 patients). Italics (2 lower rows), miRNA that are not overexpressed in inflamed UC (mir-196a) or CD (mir-30c).

Found at: doi:10.1371/journal.pone.0013160.s010 (0.02 MB XLS)

**Table S6** Compilation of the characteristics of the miRNA with significantly altered expression in quiescent UC and CD colonic mucosa. Access\_N°, MIMAT identification number; Gene-Id, miRNA gene identification number; Coordinates, coordinate of the miRNA gene on the chromosome [strand] (from [http://www.mirbase.org/cgi-bin/mirna\\_summary.pl?org=hsa](http://www.mirbase.org/cgi-bin/mirna_summary.pl?org=hsa)); Band, Chromosomal band where the miRNA gene is localized; Gene Context, presence or absence (intergenic) of overlap between the miRNA gene and another gene either on the same or on the opposite strand.

Found at: doi:10.1371/journal.pone.0013160.s011 (0.05 MB XLS)

**Table S7** Compilation of the sub-chromosomal regions where acknowledged IBD-susceptibility loci and miRNA genes with altered expression colocalize. Chromosomal locations where colocalize miRNA genes with altered expression relative to healthy controls in quiescent and/or inflamed UC or CD tissues and (i) acknowledged IBD susceptibility loci or (ii) replicated sub-chromosomal regions identified in GWAS are listed. The location of each IBD susceptibility loci is reminded. Gene-Id, miRNA gene identification number; Locus, chromosomal band where the miRNA gene is localized; Quiescent, non-inflamed; Both, non-inflamed and inflamed; +/-, +: overexpression; -: underexpression.

Found at: doi:10.1371/journal.pone.0013160.s012 (0.01 MB XLSX)

**Table S8** Alteration of miRNA expression in the colonic mucosa of UC and CD patients: in silico characterization of target transcripts. The exhaustive list of genes which are putatively targeted by the subset of 8 miRNAs that share common dysregulated overexpression in both UC and CD was downloaded from the PITA catalog of predicted human microRNA targets ([http://genie.weizmann.ac.il/pubs/mir07/mir07\\_data.html](http://genie.weizmann.ac.il/pubs/mir07/mir07_data.html)). The algorithm makes use of the parameter-free model for miRNA-target interaction described by Kertesz et al. (2007). Genes involved in a common biological process are listed together. Bold characters: strictly down regulated genes (the 3'-UTR of which interacts only with up-regulated miRNA(s))

Found at: doi:10.1371/journal.pone.0013160.s013 (0.08 MB XLS)

## Author Contributions

Conceived and designed the experiments: EOD. Performed the experiments: MF EP DCH FD. Analyzed the data: CR AG. Contributed reagents/materials/analysis tools: XT TA JCS YB. Wrote the paper: AG. Contributed to the experiments: CG. Expert gastrointestinal pathologist who assessed mucosal damage and inflammatory cells infiltration: DCH. Contributed to study design: RM ML.

## References

- Schreiber S, Rosenstiel P, Albrecht M, Hampe J, Krawczak M (2005) Genetics of Crohn disease, an archetypal inflammatory barrier disease. *Nat Rev Genet* 6: 376–88.
- Kugathasan S, Amre D (2006) Inflammatory bowel disease—environmental modification and genetic determinants. *Pediatr Clin North Am* 53: 727–49.
- Liu L, Li Y, Tollefsbol TO (2008) Gene-environment interactions and epigenetic basis of human diseases. *Curr Issues Mol Biol* 10: 25–36.
- Bouma G, Strober W (2003) The immunological and genetic basis of inflammatory bowel disease. *Nat Rev Immunol* 3: 521–33.

5. Farmer RG, Easley KA, Rankin GB (1993) Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients. *Dis Dis Sci* 38: 1137–46.
6. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, et al. (1990) Predictability of the postoperative course of Crohn's disease. *Gastroenterology* 99: 956–63.
7. Kaser A, Lee AH, Franke A, Glickman JN, Zeissig S, et al. (2008) XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. *Cell* 134: 743–56.
8. Ahn SH, Shah YM, Inoue J, Morimura K, Kim I, et al. (2008) Hepatocyte nuclear factor 4alpha in the intestinal epithelial cells protects against inflammatory bowel disease. *Inflamm Bowel Dis* 14: 908–20.
9. Paavola-Sakki P, Ollikainen V, Helio T, Halme L, Turunen U, et al. (2003) Genome-wide search in Finnish families with inflammatory bowel disease provides evidence for novel susceptibility loci. *Eur J Hum Genet* 11: 112–20.
10. Vermeire S, Rutgeerts P (2005) Current status of genetics research in inflammatory bowel disease. *Genes Immun* 6: 637–45.
11. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, et al. (2008) Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. *Nat Genet* 40: 955–62.
12. Franke A, Balschun T, Karlsen TH, Hedderich J, May S, et al. (2008) Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis. *Nat Genet* 40: 713–5.
13. Franke A, Balschun T, Karlsen TH, Svontoraityte J, Nikolaus S, et al. (2008) Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. *Nat Genet* 40: 1319–23.
14. Kugathasan S, Baldassano RN, Bradfield JP, Sleiman PM, Imielinski M, et al. (2008) Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease. *Nat Genet* 40: 1211–5.
15. Mathew CG (2008) New links to the pathogenesis of Crohn disease provided by genome-wide association scans. *Nat Rev Genet* 9: 9–14.
16. Fisher SA, Tremelling M, Anderson CA, Gwilliam R, Bumpstead S, et al. (2008) Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. *Nat Genet* 40: 710–2.
17. Imielinski M, Baldassano RN, Griffiths A, Russell RK, Annesse V, et al. (2009) Common variants at five new loci associated with early-onset inflammatory bowel disease. *Nat Genet* 41: 1335–40.
18. Asano K, Matsushita T, Umeno J, Hosono N, Takahashi A, et al. (2009) A genome-wide association study identifies three new susceptibility loci for ulcerative colitis in the Japanese population. *Nat Genet* 41: 1325–9.
19. Barrett JC, Lee JC, Lees CW, Prescott NJ, Anderson CA, et al. (2009) Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. *Nat Genet* 41: 1330–4.
20. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, et al. (2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. *Nature* 411: 599–603.
21. Parkes M, Barrett JC, Prescott NJ, Tremelling M, Anderson CA, et al. (2007) Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. *Nat Genet* 39: 830–2.
22. Hampe J, Franke A, Rosenstiel P, Till A, Teuber M, et al. (2007) A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. *Nat Genet* 39: 207–11.
23. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, et al. (2006) A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. *Science* 314: 1461–3.
24. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, et al. (2001) A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. *Nature* 411: 603–6.
25. Cho JH, Weaver CT (2007) The genetics of inflammatory bowel disease. *Gastroenterology* 133: 1327–39.
26. Noble CL, Abbas AR, Cornelius J, Lees CW, Ho GT, et al. (2008) Regional variation in gene expression in the healthy colon is dysregulated in ulcerative colitis. *Gut* 57: 1398–405.
27. Olsen J, Gerdts TA, Seidelin JB, Csillag C, Bjerrum JT, et al. (2009) Diagnosis of ulcerative colitis before onset of inflammation by multivariate modeling of genome-wide gene expression data. *Inflamm Bowel Dis* 15: 1032–8.
28. Dooley TP, Curto EV, Reddy SP, Davis RL, Lambert GW, et al. (2004) Regulation of gene expression in inflammatory bowel disease and correlation with IBD drugs: screening by DNA microarrays. *Inflamm Bowel Dis* 10: 1–14.
29. Lawrance IC, Fiocchi C, Chakravarti S (2001) Ulcerative colitis and Crohn's disease: distinctive gene expression profiles and novel susceptibility candidate genes. *Hum Mol Genet* 10: 445–56.
30. Dieckgraefe BK, Stenson WF, Korzenik JR, Swanson PE, Harrington CA (2000) Analysis of mucosal gene expression in inflammatory bowel disease by parallel oligonucleotide arrays. *Physiol Genomics* 4: 1–11.
31. Costello CM, Mah N, Hasler R, Rosenstiel P, Waetzig GH, et al. (2005) Dissection of the inflammatory bowel disease transcriptome using genome-wide cDNA microarrays. *PLoS Med* 2: e199.
32. von Stein P, Lofberg R, Kuznetsov NV, Gielen AW, Persson JO, et al. (2008) Multigene analysis can discriminate between ulcerative colitis, Crohn's disease, and irritable bowel syndrome. *Gastroenterology* 134: 1869–81; quiz 2153–4.
33. Doench JG, Sharp PA (2004) Specificity of microRNA target selection in translational repression. *Genes Dev* 18: 504–11.
34. Flynt AS, Lai EC (2008) Biological principles of microRNA-mediated regulation: shared themes amid diversity. *Nat Rev Genet* 9: 831–42.
35. Wu L, Fan J, Belasco JG (2006) MicroRNAs direct rapid deadenylation of mRNA. *Proc Natl Acad Sci U S A* 103: 4034–9.
36. Filipowicz W, Bhattacharyya SN, Sonenberg N (2008) Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? *Nat Rev Genet* 9: 102–14.
37. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, et al. (2000) The 21-nucleotide let-7 RNA regulates developmental timing in *Caenorhabditis elegans*. *Nature* 403: 901–6.
38. Miska EA (2005) How microRNAs control cell division, differentiation and death. *Curr Opin Genet Dev* 15: 563–8.
39. Kapsimali M, Kloosterman WP, de Bruijn E, Rosa F, Plasterk RH, et al. (2007) MicroRNAs show a wide diversity of expression profiles in the developing and mature central nervous system. *Genome Biol* 8: R173.
40. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, et al. (2005) MicroRNA expression profiles classify human cancers. *Nature* 435: 834–8.
41. Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. *Nat Rev Cancer* 6: 857–66.
42. Volinia S, Calin GA, Liu CG, Cimmino A, et al. (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. *Proc Natl Acad Sci U S A* 103: 2257–61.
43. Andres E, Cubedo E, Agirre X, Malumbres R, Zarate R, et al. (2006) Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. *Mol Cancer* 5: 29.
44. Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz LA, Jr., et al. (2006) The colorectal microRNAome. *Proc Natl Acad Sci U S A* 103: 3687–92.
45. Kloosterman WP, Lagendijk AK, Ketting RF, Moulton JD, Plasterk RH (2007) Targeted inhibition of miRNA maturation with morpholinos reveals a role for miR-375 in pancreatic islet development. *PLoS Biol* 5: e203.
46. Eisenberg I, Eran A, Nishino I, Moggio M, Lamperti C, et al. (2007) Distinctive patterns of microRNA expression in primary muscular disorders. *Proc Natl Acad Sci U S A* 104: 17016–21.
47. O'Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D (2007) MicroRNA-155 is induced during the macrophage inflammatory response. *Proc Natl Acad Sci U S A* 104: 1604–9.
48. Moschos SA, Williams AE, Perry MM, Birrell MA, Belvisi MG, et al. (2007) Expression profiling in vivo demonstrates rapid changes in lung microRNA levels following lipopolysaccharide-induced inflammation but not in the anti-inflammatory action of glucocorticoids. *BMC Genomics* 8: 240.
49. Sonkoly E, Stahle M, Pivarcsi A (2008) MicroRNAs: novel regulators in skin inflammation. *Clin Exp Dermatol* 33: 312–5.
50. Sonkoly E, Pivarcsi A (2009) Advances in microRNAs: implications for immunity and inflammatory diseases. *J Cell Mol Med* 13: 24–38.
51. Wu F, Zikusoka M, Trindade A, Dassopoulos T, Harris ML, et al. (2008) MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha. *Gastroenterology* 135: 1624–35 e24.
52. Allez M, Tieng V, Nakazawa A, Treton X, Pacault V, et al. (2007) CD4+ NKG2D+ T cells in Crohn's disease mediate inflammatory and cytotoxic responses through MICA interactions. *Gastroenterology* 132: 2346–58.
53. Bonen DK, Cho JH (2003) The genetics of inflammatory bowel disease. *Gastroenterology* 124: 521–36.
54. Van Limbergen J, Russell RK, Nimmo ER, Satsangi J (2007) The genetics of inflammatory bowel disease. *Am J Gastroenterol* 102: 2820–31.
55. Van Limbergen J, Wilson DC, Satsangi J (2009) The genetics of Crohn's disease. *Annu Rev Genomics Hum Genet* 10: 89–116.
56. Xu H, Cheung IY, Guo HF, Cheung NK (2009) MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. *Cancer Res* 69: 6275–81.
57. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, et al. (2009) Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. *Cell* 137: 1005–17.
58. Flavin R, Smyth P, Barrett C, Russell S, Wen H, et al. (2009) miR-29b expression is associated with disease-free survival in patients with ovarian serous carcinoma. *Int J Gynecol Cancer* 19: 641–7.
59. Sander S, Bullinger L, Wirth T (2009) Repressing the repressor: a new mode of MYC action in lymphomagenesis. *Cell Cycle* 8: 556–9.
60. Yan LX, Huang XF, Shao Q, Huang MY, Deng L, et al. (2008) MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. *Rna* 14: 2348–60.
61. Ferretti E, De Smaele E, Miele E, Laneve P, Po A, et al. (2008) Concerted microRNA control of Hedgehog signalling in cerebellar neuronal progenitor and tumour cells. *Embo J* 27: 2616–27.
62. Gebeshuber CA, Zatloukal K, Martinez J (2009) miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. *EMBO Rep* 10: 400–5.
63. Musiyenko A, Bitko V, Barik S (2008) Ectopic expression of miR-126\*, an intronic product of the vascular endothelial EGF-like 7 gene, regulates protein translation and invasiveness of prostate cancer LNCaP cells. *J Mol Med* 86: 313–22.
64. Park SY, Lee JH, Ha M, Nam JW, Kim VN (2009) miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. *Nat Struct Mol Biol* 16: 23–9.

65. Li Z, Lu J, Sun M, Mi S, Zhang H, et al. (2008) Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. *Proc Natl Acad Sci U S A* 105: 15535–40.
66. Zhou Q, Souba WW, Croce CM, Verne GN (2010) MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome. *Gut* 59: 775–84.
67. Hollander D (1999) Intestinal permeability, leaky gut, and intestinal disorders. *Curr Gastroenterol Rep* 1: 410–6.
68. Lennard-Jones JE (1989) Classification of inflammatory bowel disease. *Scand J Gastroenterol Suppl* 170: 2–6; discussion 16–9.
69. Harvey RF, Bradshaw JM (1980) A simple index of Crohn's-disease activity. *Lancet* 1: 514.
70. Xiao Li F, Sutherland LR (2002) Assessing disease activity and disease activity indices for inflammatory bowel disease. *Curr Gastroenterol Rep* 4: 490–6.
71. Gomes P, du Boulay C, Smith CL, Holdstock G (1986) Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. *Gut* 27: 92–5.
72. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2<sup>-Delta Delta C(T)</sup> Method. *Methods* 25: 402–8.
73. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, et al. (2009) The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. *Clin Chem* 55: 611–22.
74. Burns M, Valdivia H (2008) Modelling the limit of detection in real-time quantitative PCR. *Eur Food Res Technol* 226: 1513–24.
75. Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E (2007) The role of site accessibility in microRNA target recognition. *Nat Genet* 39: 1278–84.
76. Megraw M, Sethupathy P, Corda B, Hatzigeorgiou AG (2007) miRGen: a database for the study of animal microRNA genomic organization and function. *Nucleic Acids Res* 35: D149–55.
77. MacQueen J. Some methods for classification and analysis of multivariate observations. In: Le Cam LMaN J, ed. *Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability*. Berkeley/California: University of California Press 1967, 281–97.
78. Tukey JW. Box-and-Whisker Plots. *Exploratory Data Analysis*. ReadingMA: Addison-Wesley 1977, 39–43.